The GHG emissions and economic performance of the Colombian palm oil sector; current status and long-term perspectives

Increasing oil palm plantations, both for obtaining crude palm oil (CPO) and for the production of biobased products, have generated growing concern about the impact of greenhouse gas (GHG) emissions on the environment. Colombia has the potential to produce sustainable biobased products from oil palm. Nevertheless, national GHG emissions have not yet been reported by this sector. Achieving the collection of the total primary data from the oil palm sector, in Colombia, entails a tremendous challenge. Notwithstanding, for this study, the data collection of 70% of the production of fresh fruit bunches (FFB) was achieved. Therefore, current situation of CPO production in Colombia is analyzed, including 1) GHG emissions calculation, 2) net energy ratio (NER), and 3) economic performance. Moreover, the analysis includes two future scenarios, where the CPO production chain is optimized to reduce GHG emissions. Future scenario A produces biodiesel (BD), biogas, cogeneration, and compost; while future scenario B produces BD, biogas, cogeneration, and pellets. The methodology, for all the scenarios, includes life-cycle assessment and economic analysis evaluation. The results show a significant potential for improving the current palm oil production, including a 55% reduction in GHG emissions. The impact of land-use change must be mitigated to reduce GHG emissions. Therefore, a sustainable oil palm expansion should be in areas with low carbon stock or areas suitable/available to the crop (e.g., cropland, pastureland). Avoiding the deforestation of natural forests is required. Besides, crop yield should be increased to minimize the land use, using biomass to produce biobased products, and capture biogas to reduce methane emissions. In the biodiesel production life-cycle, the NER analysis shows the fossil energy consumed is lower than the renewable energy produced. Regarding the economic performance, it shows that in an optimized production chain, the capital expenditure and operational expenditure will decrease by approximately 20%

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years